Gastrointestinal · PANCE / PANRE

Chronic Pancreatitis

Irreversible fibrosis of the pancreas causing pain, exocrine insufficiency, and diabetes.

Also known as: chronic pancreatitis, CP

Overview

Chronic, progressive, fibroinflammatory disease of the pancreas characterized by irreversible structural damage leading to chronic abdominal pain, exocrine insufficiency (steatorrhea, malabsorption), and endocrine insufficiency (diabetes mellitus).

Epidemiology

Prevalence ~50 per 100,000 in the US. Higher prevalence in alcohol users and smokers. Male predominance. Increased risk of pancreatic cancer (4-fold over baseline).

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Chronic Pancreatitis outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → Sign in

Free to start · No credit card · Cancel anytime

Risk factors

Alcohol — TIGAR-O classification 'T' (Toxic) — chronic heavy use (>5 drinks/day for >5 yr)
Smoking — independent and synergistic risk; accelerates progression
Genetic — PRSS1 (hereditary pancreatitis, autosomal dominant), SPINK1, CFTR, CTRC mutations
Autoimmune pancreatitis — IgG4-related (type 1) or duct-centric (type 2, IBD-associated)
Obstructive — pancreas divisum, sphincter of Oddi dysfunction, post-traumatic stricture, neoplasm
Recurrent acute pancreatitis (any cause)
Idiopathic (~20%)
Tropical (calcific) pancreatitis (developing countries)

Pathophysiology

TIGAR-O etiologic classification (Toxic-metabolic, Idiopathic, Genetic, Autoimmune, Recurrent acute, Obstructive). Repeated acinar injury triggers stellate cell activation, collagen deposition, ductal stricture, calcification, and progressive parenchymal loss. Exocrine insufficiency develops when >90% of acinar function is lost.

Clinical presentation

Symptoms

Chronic, intermittent or constant epigastric pain — postprandial, radiates to back, may be relieved by leaning forward
Steatorrhea — pale, bulky, foul-smelling stools that float
Weight loss and malnutrition
Symptoms of diabetes (polyuria, polydipsia, fatigue)
Fat-soluble vitamin deficiency (ADEK) symptoms — bleeding (K), bone disease (D), neuropathy (E), night blindness (A)
Some patients have minimal pain (especially late-stage 'burned-out' CP)

Signs / physical exam

Cachexia, temporal wasting
Epigastric tenderness (less prominent than in acute pancreatitis)
Bronze skin (hemochromatosis with pancreatic involvement — rare)
Signs of fat-soluble vitamin deficiency
Diabetic complications

Classic findings

Triad of pancreatic calcifications + steatorrhea + diabetes mellitus is pathognomonic but late.

Differential diagnosis

Recurrent acute pancreatitis — Distinct episodes with normalization between; lipase rises and falls; may evolve to CP
Pancreatic adenocarcinoma — Painless jaundice in head tumors; mass and ductal dilation on imaging; weight loss; CA 19-9 elevated
Functional dyspepsia / IBS — Normal imaging, normal pancreatic function tests
Mesenteric ischemia — Postprandial pain, weight loss, atherosclerotic risk factors; CT angiography
Peptic ulcer / gastritis — Burning epigastric pain; EGD
Biliary disease (chronic cholestasis, PSC) — Imaging and LFTs
Pancreatic pseudocyst — Complication of CP; mass effect, pain
Cystic neoplasm (IPMN, MCN, SCA) — Cystic lesions; MRCP, EUS-FNA

Diagnostic workup

Diagnostic criteria

Established CP: characteristic imaging findings (calcifications, ductal dilation, pseudocysts) + symptoms ± exocrine/endocrine insufficiency. Early CP: more challenging; EUS Rosemont criteria, pancreatic function testing, and longitudinal observation.

Labs

Lipase/amylase — often NORMAL in established CP (atrophic gland); elevated only during flares
BMP, calcium, magnesium
Fecal elastase-1 — <200 mcg/g suggests exocrine insufficiency (<100 = severe)
72-h fecal fat collection — >7 g fat/day on 100 g fat diet confirms steatorrhea (gold standard, rarely performed)
Fasting glucose, HbA1c — screen for diabetes
Fat-soluble vitamin levels (A, D, E, K — INR as surrogate for K)
B12 (intrinsic factor and acid-dependent absorption may be affected indirectly)
Lipid panel, triglycerides
Autoimmune workup if suspected: IgG4, ANA
Genetic testing in young patients or family history (PRSS1, SPINK1, CFTR, CTRC)

Imaging

CT abdomen — pancreatic calcifications (pathognomonic), ductal dilation, parenchymal atrophy, pseudocysts
MRCP — main pancreatic duct dilation and side-branch ectasia (chain of lakes appearance); without and with secretin enhancement
EUS — most sensitive for early CP; Rosemont criteria (hyperechoic foci, hyperechoic strands, lobularity, cysts, calcifications, duct dilation, hyperechoic duct margins, side branch dilation, irregular duct contour)
ERCP — historically used for diagnosis; now mainly therapeutic (stenting, stone extraction) due to pancreatitis risk
Secretin-enhanced MRCP — assess ductal compliance and bicarbonate output

Diagnostic algorithm

TIGAR-O Category	Examples
T — Toxic-metabolic	Alcohol, smoking, hypercalcemia, hypertriglyceridemia, chronic renal failure, medications
I — Idiopathic	Early-onset, late-onset, tropical
G — Genetic	PRSS1 (hereditary), SPINK1, CFTR, CTRC
A — Autoimmune	Type 1 (IgG4-related), Type 2 (duct-centric, IBD-associated)
R — Recurrent acute	Recurrent severe AP, post-necrotic, vascular/ischemic, post-irradiation
O — Obstructive	Pancreas divisum, sphincter of Oddi dysfunction, neoplasm, post-traumatic stricture

TIGAR-O etiologic classification of chronic pancreatitis.

Treatment

First-line

Alcohol cessation (single most important intervention)
Smoking cessation (independent and synergistic risk)
Pain management: acetaminophen, NSAIDs, gabapentinoids; opioids judiciously (high addiction risk); tricyclic antidepressants for neuropathic component
Pancreatic enzyme replacement therapy (PERT) — pancrelipase 25,000-75,000 lipase units with meals and 10,000-25,000 with snacks; uncoated formulation with concurrent PPI for some patients
Treat diabetes — insulin often required (type 3c diabetes — brittle, prone to hypoglycemia due to glucagon deficiency)
Nutritional support: low-fat diet only if severe steatorrhea; supplement fat-soluble vitamins (ADEK), calcium, B12
Manage osteopenia/osteoporosis (DEXA, vitamin D, bisphosphonates)

Second-line / adjunct

Endoscopic therapy: ERCP with pancreatic duct stenting, stone extraction, ESWL for large stones — selected patients with ductal disease
Surgical decompression — lateral pancreaticojejunostomy (Puestow) for dilated main duct (>7 mm) and refractory pain; Frey, Beger, or Whipple procedures for head-predominant disease
Celiac plexus block (limited durability)
Total pancreatectomy with islet auto-transplantation — refractory pain with debilitating disease (specialized centers)
Treat IgG4-related autoimmune pancreatitis with corticosteroids — DRAMATIC response (often confused with cancer); maintain with low-dose steroid or rituximab

Complications

Chronic pain and opioid dependence
Exocrine insufficiency — steatorrhea, malnutrition, fat-soluble vitamin deficiency, B12 deficiency
Endocrine insufficiency — diabetes mellitus (type 3c — brittle, hypoglycemia-prone)
Pancreatic pseudocyst (drainage if symptomatic, infected, or persistent)
Pseudoaneurysm (splenic artery) → hemorrhage
Splenic vein thrombosis → isolated gastric varices (sinistral hypertension)
Biliary stricture from pancreatic head fibrosis → obstructive jaundice
Duodenal stricture / gastric outlet obstruction
Pancreatic adenocarcinoma (4× baseline risk; higher in hereditary pancreatitis)
Osteoporosis

PANCE pearls

Lipase is often NORMAL in established CP — atrophic gland produces less enzyme. Do not exclude CP based on normal lipase.
Pancreatic calcifications + steatorrhea + diabetes = late-stage CP (textbook triad).
Type 3c diabetes (pancreatogenic) is brittle and prone to severe hypoglycemia from glucagon deficiency — counsel patients and consider continuous glucose monitoring.
Pancreatic enzyme replacement (PERT) — dose 25,000-50,000 lipase units per meal; concurrent PPI for non-enteric-coated formulations; titrate to symptom control.
Always exclude pancreatic cancer in patients with new or worsening pain — CT, MRI, EUS-FNA as indicated.
IgG4-related autoimmune pancreatitis (type 1) responds dramatically to corticosteroids — sausage-shaped pancreas, elevated IgG4, other organ involvement (sclerosing cholangitis, retroperitoneal fibrosis, sialadenitis).
PRSS1 mutation (hereditary pancreatitis) — 80% lifetime risk of CP; consider screening for pancreatic cancer.
Smoking accelerates CP progression independently — counseling cessation is critical.
Total pancreatectomy with islet auto-transplantation can be considered in highly selected refractory patients at experienced centers.
Tropical (juvenile) calcific pancreatitis: developing countries; SPINK1 mutations; large ductal stones; presents in adolescence with severe pain and diabetes.

References

ACG 2020 — Gardner TB et al. ACG Clinical Guideline: Chronic Pancreatitis. Am J Gastroenterol 2020;115:322-339
AGA 2020 — Singh VK et al. AGA Clinical Practice Update on Evaluation and Management of Exocrine Pancreatic Insufficiency: Expert Review. Gastroenterology 2020;159:1972-1987
International Consensus — Whitcomb DC et al. International consensus guidelines for nutrition therapy in pancreatitis. Pancreatology 2018;18:847-854

Practice Gastrointestinal questions on FirstPassPA

Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.